Navigation Links
InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
Date:2/21/2013

nd involve risks and uncertainties as of the date of this release, including without limitation InterMune's expectation regarding its anticipated timing of concluding pricing and reimbursement discussions and/or initiating commercial launches for Esbriet in various European countries; the estimated size of the patient population in Canada suffering from IPF and InterMune's expectations with respect to Canada of securing coverage from private insurance plans and reimbursement from public (provincial) drug reimbursement plans including the timing thereof; InterMune's expectation regarding the results of the ASCEND study and the prospects of success thereof and meeting the goal of bringing Esbriet to IPF patients in the United States;  InterMune's expectation in building its Esbriet franchise in North America; InterMune's intent to repurchase the remaining $18.4 million of the outstanding 2015 notes; and InterMune's projected revenue from sales of Esbriet and operating expenses for 2013.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 29, 2012 (the "Form 10-K"), most recent quarterly report on Form 10-Q filed with the SEC on November 9, 2012 (the "Form 10-Q"), and other periodic reports filed with the SEC, including but not limited to the following: (i) the risks related to the uncertain, lengthy and expensive clinical development process for the company's produc
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
2. InterMune to Present at J. P. Morgan Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune To Present At JMP Securities Healthcare Conference
5. InterMune To Release Third Quarter Financial Results On November 7
6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015 Oxford Finance LLC ... to life sciences and healthcare services companies, today announced ... loan agreement with Celula, Inc., a diagnostic testing company ... enabling better patient care and improved outcomes.  Proceeds of ... and expand the commercialization of its products in the ...
(Date:4/30/2015)... 30, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... of biosimilar therapeutics including high value and difficult ... its previously announced underwritten public offering of 6,750,000 ... offering price of $15.50 per share. This includes ... their option to purchase up to 750,000 additional ...
(Date:4/30/2015)... April 30, 2015 Available in ... http://www.lespausa.com , Fleur’s introduces ... combining the benefits of makeup, skin care and ... tinted cream is designed with specific complexion-correcting pigments ... even complexion and a healthy glow. Far more ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Sterlitech ... ultrafiltration membranes, the PX, PY, and PZ ... sheets, and disks. Designed to be ideal ... new membranes can fill critical process requirements where ... downstream processes. , “New regulations on industrial wastewater ...
Breaking Biology Technology:Oxford Finance Provides $10 Million Debt Financing to Celula 2Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Sterlitech Offers New Ultrafiltration Membranes 2
... to $33.2 Million, ... $12.8 Million, -- The Company Provides ... NEW YORK and HAIKOU, Hainan, China, March 31,/Xinhua-PRNewswire-FirstCall/ -- ... which develops, manufactures, and,markets generic and branded bio-pharmaceutical products ...
... on Lead Compounds That Directly and Specifically Activate ... ... Massachusetts, March 31 Mercury Therapeutics,Inc. (MTI), a company that discovers ... filed for patent protection on,three lead compounds that directly and specifically ...
... Vaccine Technology and ... Bird Flu Clinical Program, Webcast/teleconference Call Set ... March 31 Carrington,Laboratories, Inc. (OTC Bulletin Board: CARN) today reported ... ($0.90) per basic and,diluted share, for the year ended December 31, ...
Cached Biology Technology:China Pharma Holdings, Inc. Announces Record 2007 Year End Results 2China Pharma Holdings, Inc. Announces Record 2007 Year End Results 3China Pharma Holdings, Inc. Announces Record 2007 Year End Results 4China Pharma Holdings, Inc. Announces Record 2007 Year End Results 5China Pharma Holdings, Inc. Announces Record 2007 Year End Results 6China Pharma Holdings, Inc. Announces Record 2007 Year End Results 7China Pharma Holdings, Inc. Announces Record 2007 Year End Results 8China Pharma Holdings, Inc. Announces Record 2007 Year End Results 9China Pharma Holdings, Inc. Announces Record 2007 Year End Results 10China Pharma Holdings, Inc. Announces Record 2007 Year End Results 11Mercury Therapeutics Patents Filed 2Mercury Therapeutics Patents Filed 3Carrington Reports 2007 Financial Results 2Carrington Reports 2007 Financial Results 3Carrington Reports 2007 Financial Results 4Carrington Reports 2007 Financial Results 5Carrington Reports 2007 Financial Results 6Carrington Reports 2007 Financial Results 7
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
(Date:3/23/2015)... --  HOYOS Labs , a leading global authentication infrastructure ... Company will demonstrate multiple biometrics-based technologies under its identity ... on March 23 through 25, 2015, in ... IEEE Biometric Open Protocol Standard; free biometrics-based consumer app, ... system. BOPS was invented by HOYOS Labs and contributed ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ... "India Sensors Market Forecast and Opportunities 2020" ... market is projected to grow at a CAGR ... automotive, industrial and healthcare sectors are the key ... addition, adoption of MEMS technology in sensors is ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... . . . ,Researchers at the Bio-SANS instrument ... and small-angle neutron scattering to get a first insight ... complexes. The unique properties of polyelectrolyte materials are of ... membrane -- three-dimensional bio-scaffolds to grow cells for regenerating ...
... of Medicine, Hershey, Pennsylvania have discovered that the presence ... which mediates the inhibitory action of opioid growth factor ... the progression and treatment of human ovarian cancer. ... engineered to have a reduced expression of OGFr, into ...
... threats to tropical coral reefs can be a population outbreak ... can consume live corals over large areas, a change that ... the aesthetic value of coral reefs, which in turn negatively ... triggers and spread of COT outbreaks are not fully understood. ...
Cached Biology News:Feb. 21, 2012, story tips 2Feb. 21, 2012, story tips 3A breakthrough in understanding the biology and treatment of ovarian cancer 2A breakthrough in understanding the biology and treatment of ovarian cancer 3Coral-eating sea star invaders turn out to be locals 2
... making flow cytometry accessible to anyone in the ... latest addition to Guavas on-demand microcapillary flow cytometry ... to use, surprisingly affordable, very compact, and nicely ... The Guava EasyCyte Mini has all of the ...
... unique combination of Coulter volume and ... and accurate cell counting. This flow ... UV, allowing flexible fluorochrome selection for ... only achievable with larger, more expensive ...
... crosslinked to protein G-agarose beads which can ... heart mitochondria. Also included are 2 mg ... ,The pyruvate dehydrogenase complex (PDH) immunocapture kit ... of tissue. This facilitates the subsequent analysis ...
... Protein/antibody delivery using PULSin may be superior ... example, unlike traditional transfection, with PULSin you ... level and time course of proteins in ... provide more information than traditional RNA interference ...
Biology Products: